Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2022.28.6.657
Abstract: BACKGROUND: Among patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC), incidence of brain metastases (BMs) is relatively high and increasing. Despite the high unmet need for patients with HER2+ MBC… read more here.
Keywords: seagen inc; seagen; patients her2; among patients ... See more keywords